Could cannabinoid biosynthesis be the next big thing for investors?

Published on 19 November 2021

Legalisation, increasing acceptance of and growing demand for pharmaceutical and consumer products mean the cannabinoids industry is booming. Will biosynthesis take it to new heights?

Writer and journalist Vivienne Parry speaks to Randy Baron of Pinnacle Associates, Roy Lipski of Creo, Trevor Peters of Willow Biosciences and Nick Davis of Memery Crystal as they discuss the opportunity for investors and how biosynthesis will affect the direction of cannabinoids.

This is the cannabinoids conversation you won’t want to miss.

Share this with friends and colleagues